Kyungdong Pharmaceutical Decides to Buy Back 3 Billion KRW Worth of Treasury Shares... "Actively Implementing Shareholder Value Enhancement Policy"

[Asia Economy Reporter Hyunseok Yoo] Kyungdong Pharmaceutical announced on the 17th that it has decided to acquire treasury shares worth 3 billion KRW. The acquisition period is from the 18th of this month to November 17.

A company official stated, “We decided to repurchase treasury shares to enhance shareholder value,” adding, “Going forward, we will actively pursue shareholder-friendly policies such as treasury share repurchases and dividends based on abundant cash liquidity and stable performance.”

Kyungdong Pharmaceutical continuously repurchases treasury shares by leveraging its stable financial structure and abundant funds. In May, it completed the acquisition of treasury shares worth 2.6 billion KRW. Currently, Kyungdong Pharmaceutical holds a total of 3,274,996 treasury shares, accounting for 10.6% of the total issued shares.

As part of its shareholder return policy, the company maintains a high dividend payout ratio. In line with the semi-annual closing date, Kyungdong Pharmaceutical decided to implement a quarterly dividend of 100 KRW per common share. Through the settlement dividend conducted in April this year, it also paid a total dividend of 11 billion KRW.

Kyungdong Pharmaceutical is a specialty pharmaceutical company with strengths in chronic disease product lines such as hyperlipidemia and hypertension. It has secured a leading position in sales targeting private clinics. Growth in the over-the-counter drug sector is also expected through the expansion of the product lines of ‘Geunal-en,’ famous for its advertisement featuring popular singer IU, and the health functional food brand ‘Nature With.’

In June, Kyungdong Pharmaceutical completed the establishment of a second-generation management system with the sole appointment of CEO Ryu Gi-seong. The company plans to actively pursue new growth engines through bold investments and new business initiatives.

This content was produced with the assistance of AI translation services.